Avet-Loiseau H - Search Results

1

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, Karlin L, Perrot A, Touzeau C, Chrétien ML, Rigaudeau S, Dib M, Nicolas-Virelizier E, Escoffre-Barbe M, Belhadj K, Mariette C, Stoppa AM, Araujo C, Doyen C, Fontan J, Kolb B, Garderet L, Brechignac S, Malfuson JV, Jaccard A, Lenain P, Borel C, Hebraud B, Benbrahim O, Dorvaux V, Manier S, Augeul-Meunier K, Vekemans MC, Randriamalala E, Chaoui D, Caers J, Chaleteix C, Benboubker L, Vincent L, Glaisner S, Zunic P, Slama B, Eveillard JR, Humbrecht-Kraut C, Morel V, Mineur P, Eisenmann JC, Demarquette H, Richez V, Vignon M, Caillot D, Facon T, Moreau P, Colin AL, Olivier P, Wuilleme S, Avet-Loiseau H, Corre J, Attal M. Roussel M, et al. Blood. 2022 May 5;139(18):2747-2757. doi: 10.1182/blood.2021014635. Blood. 2022. PMID: 35511184 Free article. Clinical Trial.

2

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R; Intergroupe Francophone du Myélome. Avet-Loiseau H, et al. Blood. 2002 Mar 15;99(6):2185-91. doi: 10.1182/blood.v99.6.2185. Blood. 2002. PMID: 11877296 Free article.

3

Current treatment strategies for multiple myeloma.

Grosbois B, Decaux O, Azais I, Facon T, Avet-Loiseau H. Grosbois B, et al. Eur J Intern Med. 2002 Mar;13(2):85-95. doi: 10.1016/s0953-6205(01)00205-9. Eur J Intern Med. 2002. PMID: 11893464

4

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H; Intergroupe Francophone du Myélome. Moreau P, et al. Blood. 2002 Sep 1;100(5):1579-83. doi: 10.1182/blood-2002-03-0749. Blood. 2002. PMID: 12176874 Free article.

5

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.

Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, Bertucci F, Birnbaum D, Nguyen C, Harousseau JL, Bataille R, Houlgatte R, Minvielle S. Magrangeas F, et al. Blood. 2003 Jun 15;101(12):4998-5006. doi: 10.1182/blood-2002-11-3385. Epub 2003 Mar 6. Blood. 2003. PMID: 12623842 Free article.

6

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, Harousseau JL, Bataille R. Robillard N, et al. Blood. 2003 Aug 1;102(3):1070-1. doi: 10.1182/blood-2002-11-3333. Epub 2003 Apr 17. Blood. 2003. PMID: 12702507 Free article.

7

Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level.

Magrangeas F, Cormier ML, Descamps G, Gouy N, Lodé L, Mellerin MP, Harousseau JL, Bataille R, Minvielle S, Avet-Loiseau H. Magrangeas F, et al. Blood. 2004 May 15;103(10):3869-75. doi: 10.1182/blood-2003-07-2501. Epub 2004 Jan 8. Blood. 2004. PMID: 14715636 Free article.

8

Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.

Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, Harousseau JL, Bataille R. Moreau P, et al. Haematologica. 2004 May;89(5):547-51. Haematologica. 2004. PMID: 15136217

9

Stem-cell transplantation in multiple myeloma.

Harousseau JL, Moreau P, Attal M, Facon T, Avet-Loiseau H. Harousseau JL, et al. Best Pract Res Clin Haematol. 2005;18(4):603-18. doi: 10.1016/j.beha.2005.01.005. Best Pract Res Clin Haematol. 2005. PMID: 16026740 Review.

10

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL. Chevallier P, et al. Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8. Leuk Res. 2005. PMID: 16038726

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

362 results

Search Page

Filters